![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The net proceeds will be used for the development of chimeric antigen receptor T cell therapy program, at an advanced stage for Cellogen Therapeutics, where the T cells of the patients are genetically engineered to identify and kill the cancer cells.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 18, 2024